AVITA Medical to Participate in Lake Street’s BIG8 Investment Conference
AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a company in regenerative medicine focused on wound care and skin restoration, will participate in Lake Street Capital Markets’ 8th Annual Best Ideas Growth (BIG8) Conference in New York. The investor-focused event offers AVITA Medical a forum to share progress, highlight its technology, and outline priorities for the period ahead.
Meet the Leadership Team
AVITA Medical’s Chief Executive Officer, Jim Corbett, will lead the company’s presence at the conference. He plans to hold one-on-one meetings with institutional investors, offering a direct look at the company’s strategy and product portfolio. These conversations give investors a chance to ask questions, hear how plans are being executed, and understand where AVITA sees the most opportunity—while allowing the company to demonstrate its growth potential in a competitive market.
Innovative Solutions from AVITA Medical
AVITA Medical’s flagship technology is the RECELL System, a first-in-class approach cleared by the U.S. Food and Drug Administration for multiple uses. It’s approved for treating severe burn wounds and extensive skin defects. The system also enables the repigmentation of stable vitiligo lesions, extending its role in skin restoration for appropriate patients.
How the RECELL System Works
The RECELL System uses a patient’s own skin to create Spray-On Skin Cells at the point of treatment. By preparing cells where care is delivered, clinicians can support healing in a timely, targeted way. This approach is designed to enhance the healing process and improve patient outcomes by streamlining care when and where it’s needed.
Global Use and Recognition
RECELL’s impact extends beyond the United States. The system is approved for use in Australia, Europe, and Japan, reflecting compliance with rigorous international standards. These approvals underscore its relevance across a range of skin healing needs and broaden AVITA Medical’s reach in key global markets.
Additional Product Offerings
Alongside RECELL, AVITA Medical holds exclusive rights to market PermeaDerm, a biosynthetic wound matrix, and Cohealyx, a collagen-based dermal matrix. Together, these products align with the company’s mission to elevate standards in wound care and give clinicians options intended to address varied patient needs.
Future Growth and Investor Engagement
Participation in the BIG8 Conference is part of AVITA Medical’s ongoing engagement with the investment community. By discussing advancements, strategy, and execution with investors, the company emphasizes its focus on innovation and its trajectory within regenerative medicine. The setting also provides a clear space to discuss progress, priorities, and the path ahead.
Getting in Touch
Institutions or investors interested in learning more—or arranging a meeting during the conference—are encouraged to contact Lake Street representatives. These conversations provide a first-hand view of AVITA Medical’s current initiatives and potential for growth, while helping build long-term relationships within the investment community.
Frequently Asked Questions
What is the RECELL System?
The RECELL System is a first-in-class medical technology that uses a patient’s own skin to generate Spray-On Skin Cells at the point of treatment. It’s FDA approved for severe burn wounds and extensive skin defects and also enables repigmentation of stable vitiligo lesions.
Where is the BIG8 Conference located?
The 8th Annual Best Ideas Growth (BIG8) Conference will be held in New York and is hosted by Lake Street Capital Markets.
Who is the CEO of AVITA Medical?
Jim Corbett is the Chief Executive Officer of AVITA Medical. He’ll lead the company’s participation at the conference and hold one-on-one meetings with institutional investors.
What other products does AVITA Medical offer?
In addition to the RECELL System, AVITA Medical has exclusive rights to market PermeaDerm, a biosynthetic wound matrix, and Cohealyx, a collagen-based dermal matrix.
How is AVITA Medical contributing to international markets?
RECELL is approved for use in Australia, Europe, and Japan, reflecting compliance with international standards and expanding access to AVITA Medical’s skin-healing technology in those regions.
